Funding for this research was provided by:
National Institute of Mental Health (U01MH106883, U01MH106882, U01MH106893, U01MH106874, U01MH106892, U01MH106876, U01MH108898, U01MH106884, U01MH106891)
Received: 22 September 2020
Accepted: 1 February 2021
First Online: 29 March 2021
Ethics approval and consent to participate
: The analyzed samples were de-identified and derived from an individual postmortem, and IRB approval was not required by any of the participating institutions. The external data we utilized was generated as part of the 1000 Genomes Project and has unrestricted access.The experimental methods comply with the Helsinki Declaration.
: J.V.M. is an inventor on patent US6150160, is a paid consultant for Gilead Sciences, serves on the scientific advisory board of Tessera Therapeutics Inc. (where he is paid as a consultant and has equity options), and currently serves on the American Society of Human Genetics Board of Directors. The other authors do not declare competing interests.